1 **Title**

2 Omics-Based Interaction Framework – a systems model to reveal molecular drivers of synergy

3

4 **Authors**

5 Jezreel Pantaleón García¹, Vikram V. Kulkarni^{1,2}, Tanner C. Reese^{1,3}, Shradha Wali^{1,2}, Saima J. Wase¹,
6 Jiexin Zhang⁴, Ratnakar Singh⁵, Mauricio S. Caetano¹, Seyed Javad Moghaddam¹, Faye M. Johnson⁵,
7 Jing Wang⁴, Yongxing Wang¹, Scott E. Evans^{1,2}

8 ¹ Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston,
9 Texas, USA 77030

10 ² MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas,
11 USA 77030

12 ³ Rice University, Houston, Texas, USA, 77005

13 ⁴ Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer
14 Center, Houston, Texas, USA 77030

15 ⁵ Department of Thoracic, Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
16 Center, Houston, Texas, USA 77030

17

18 **Corresponding Author:** Scott E. Evans, MD
19 6565 MD Anderson Blvd, Unit 1059
20 Houston, TX, USA 77030
21 seevans@mdanderson.org
22 (Office) 713 – 563 – 7433

23

24 **Running Title:** Omics-Based Systems Synergy Model

25 **Final Character Count:** 64865

26 **Abstract**

27 Bioactive molecule library screening strategies may empirically identify effective combination therapies.
 28 However, without a systems theory to interrogate synergistic responses, the molecular mechanisms
 29 underlying favorable drug-drug interactions remain unclear, precluding rational design of combination
 30 therapies. Here, we introduce Omics-Based Interaction Framework (OBIF) to reveal molecular drivers
 31 of synergy through integration of statistical and biological interactions in supra-additive biological
 32 responses. OBIF performs full factorial analysis of feature expression data from single vs. dual factor
 33 exposures to identify molecular clusters that reveal synergy-mediating pathways, functions and
 34 regulators. As a practical demonstration, OBIF analyzed a therapeutic dyad of immunostimulatory small
 35 molecules that induces synergistic protection against influenza A pneumonia. OBIF analysis of
 36 transcriptomic and proteomic data identified biologically relevant, unanticipated cooperation between
 37 RelA and cJun that we subsequently confirmed to be required for the synergistic antiviral protection. To
 38 demonstrate generalizability, OBIF was applied to data from a diverse array of Omics platforms and
 39 experimental conditions, successfully identifying the molecular clusters driving their synergistic
 40 responses. Hence, OBIF is a phenotype-driven systems model that supports multiplatform exploration
 41 of synergy mechanisms.

42

43 **Keywords**

44 Data integration / Inducible epithelial resistance / Multi-Omics / Pneumonia / Synergy

45

46 **Subject Categories**

47 Genome-Scale and Integrative Biology; Methods & Resources; Microbiology, Virology & Host Pathogen
 48 Interaction

49 Introduction

50 Superior treatment outcomes are achieved for many disease states when more than one therapeutic
 51 agent is administered (Chen *et al*, 2015; Zappasodi *et al*, 2018; Ronzitti *et al*, 2018; Han *et al*, 2019).
 52 Indeed, there are many well documented instances when the therapeutic benefit of two agents
 53 administered together substantially exceeds the benefit that would be predicted by the additive effects
 54 of the agents administered individually. Widespread availability of high throughput technologies has
 55 allowed multi-level study of complex biological responses from genome to phenome (Hasin *et al*, 2017).
 56 Yet, there remains lack of consensus regarding the appropriate analysis of statistical and biological
 57 interactions found in non-additive (i.e., antagonistic or synergistic) responses (Wei *et al*, 2018).
 58 Moreover, previously proposed strategies to analyze non-additive interactions frequently lack sufficient
 59 generalizability to study these processes outside of their home Omics platforms (Chen *et al*, 2015).
 60 Thus, while synergistic therapeutic combinations may be empirically derived from fortuitous clinical
 61 experiences or through screening of bioactive small molecule libraries, the absence of an established
 62 means to investigate these favorable drug-drug interactions ultimately precludes understanding of their
 63 underlying mechanisms. Consequently, development of a methodology to integrate the statistical and
 64 biological components of synergistic interactions in diverse Omics settings can advance the rational
 65 design of combination therapies while affording understanding of their molecular mechanisms against
 66 diseases.

67
 68 Pneumonia is a major worldwide cause of death and frequently requires combination therapies
 69 (Troeger *et al*, 2017; Metlay *et al*, 2019). We have previously reported that a therapeutic dyad of
 70 immunostimulatory small molecules induces synergistic protection against a broad range of
 71 pneumonia-causing pathogens (Duggan *et al*, 2011, Cleaver *et al*, 2014, Kirkpatrick *et al*, 2018; Ware
 72 *et al*, 2019). This combination (hereafter, “Pam2-ODN”) is comprised of a Toll-like receptor (TLR) 2/6
 73 agonist, Pam2CSK4 (“Pam2”), and a TLR 9 agonist, ODN M362 (“ODN”), that stimulate protective
 74 responses from lung epithelial cells (Cleaver *et al*, 2014). This biological response, termed inducible

epithelial resistance, promotes survival benefits and microbicidal effects that significantly exceed the additive effects of the individual ligands (Duggan *et al*, 2011; Tuvim *et al*, 2012). Thus, understanding the molecular mechanisms underlying this unanticipated synergy may allow optimized manipulation of epithelial antimicrobial responses and support new generations of host-based therapeutics against infections.

In the absence of a systems theory to interrogate synergistic mechanisms (Wei *et al*, 2018), we introduce Omics-Based Interaction Framework (OBIF) to identify molecular drivers of synergy through integration of statistical and biological interactions in supra-additive biological responses. Unlike exploratory synergy models (Chen *et al*, 2015), OBIF is a phenotype-driven model (Hasin *et al*, 2017) that performs full factorial analysis (Li *et al*, 2009; Antony, 2014; Das *et al*, 2018) of feature expression data from single vs. dual factor exposures to identify molecular clusters that reveal synergy-mediating pathways, functions and regulators. To demonstrate the utility of OBIF, we applied this strategy to multi-Omics experimental data from epithelial cells exposed to Pam2-ODN to identify biologically relevant, unanticipated cooperative signaling events that we subsequently confirmed to be required for the synergistic pneumonia protection. Then, to demonstrate generalizability, OBIF was applied to datasets from diverse types of Omics platforms and experimental models, successfully identifying molecular clusters driving their synergistic responses.

Results

Synergistic Pam2-ODN-induced epithelial resistance against pneumonia

Our laboratory's interest in synergistic interactions arises from our experience investigating single vs. dual immunostimulatory treatments to prevent pneumonia (Duggan *et al*, 2011; Tuvim *et al*, 2012; Cleaver *et al*, 2014; Kirkpatrick *et al*, 2018; Ware *et al*, 2019). As a demonstrative example, data are presented here from influenza A virus (IAV) challenges of different models following pretreatment with Pam2 alone, ODN alone or the Pam2-ODN combination. When mice are challenged with IAV 24 h after

the indicated inhaled treatments, we observed little increase in survival after the individual treatments compared to sham-treated control mice, whereas mice treated with the Pam2-ODN combination demonstrated profound antiviral protection (Figure 1A). Similarly, when isolated mouse lung epithelial (MLE-15) cells were challenged with IAV 4 h after pretreatment with the individual ligands, we observed no significant reductions in the viral burden relative to PBS treated cells. However, cells pretreated with Pam2-ODN showed a substantial reduction in viral nucleoprotein (NP) gene expression as assessed by qPCR relative to host 18s gene (Figure 1B). Comparing the effect of dual ligand treatment (E_{AB}) to the expected response additivity of the individual ligand treatments ($E_A + E_B$) (Foucquier *et al*, 2015) reveals supra-additive effects on both *in vivo* survival benefits and *in vitro* viral clearance (Figure 1C). To better understand the molecular mechanisms driving such unanticipated synergy, we developed OBIF as a phenotype-driven model (Hasin *et al*, 2017) to understand favorable drug-drug interactions mediating synergistic responses and outcomes.

Development of a systems synergy model from experimental Omics data

To formally test whether the effect of dual factors (F_{AB} : Pam2-ODN) is greater than the expected linear sum of its individual factors (F_A : Pam2; F_B : ODN), an initial 2-level 2-factor (2^2) factorial design is required (Slinker, 1998; Foucquier *et al*, 2015) (Figure 1D). Our strategy adapts the traditional analysis of variance (ANOVA) approach into a model that links the empirical analysis of synergy (Slinker, 1998; Foucquier *et al*, 2015) with the high-throughput capacity and high-dimensionality of Omics datasets (Coral *et al*, 2017; Bardini *et al*, 2017). As summarized in Figure 1E, OBIF integrates statistical and biological interactions in Omics data matrices from single vs. dual factor exposures, leveraging Omics screening to promote discovery of the molecular drivers of synergy, and facilitating the biological validation of synergy regulators. The analytical pipeline is freely available as an R package at GitHub (www.github.com/evanslaboratory/OBIF). Naturally, the experimental validation components must be tailored to the individual tools and characteristics of the biological responses being studied.

Differentially expressed molecules reveal synergy-specific pathways

To investigate the mechanisms underlying Pam2-ODN synergy, we used OBIF to re-analyze previously published (Data Ref: Tuvim *et al*, 2014) lung homogenate transcriptomic data from mice inhalationally treated with single vs. dual ligands (GSE28994). After model fitting for feature expression (Figure EV1), this analysis identifies 3456 features as differentially expressed molecules (DEMs) 2 h after treatment with Pam2, 2941 DEMs after ODN treatment, and 3138 DEMs after treatment with Pam2-ODN (Figure 2A). Despite the fact that 52% (1617/3138) of DEMs were shared by Pam2-ODN and the individual ligands, enrichment analysis using IPA software revealed an overrepresentation of 12 canonical cellular immune response and cytokine signaling pathways that were activated by Pam2-ODN but not by either or both single ligands (Figure 2B). Of these, NF- κ B signaling was the most enriched signaling pathway by Pam2-ODN treatment. Although unsupervised hierarchical clustering consistently segregated the treatment groups (Figure 2C), this approach alone did not reveal distinctive gene clusters to explain the synergistic response, likely due to the 52% redundancy of DEMs between groups.

Expression profiles summarize biological interactions and disentangle effectors of synergistic functions

Rather than relying on potentially redundant DEM clusters, OBIF classifies dual factor-induced DEMs into eight expression profiles (EPs) that characterize cooperative and competitive biological interactions of individual factors (Table 1). EPs are defined by expression directionality (up- or down-regulation) of individual features and are not biased by the DEM expression analysis. Cooperative EPs have accordant expression directionality induced by F_A and F_B , while competitive EPs have opposite directionalities induced by F_A and F_B . Among the cooperative EPs, concordant profiles result when F_{AB} directionality corresponds with the single factor effects (EPs I and II), and discordant profiles occur when F_{AB} directionality opposes the single factors (III and IV). Alternatively, among the competitive EPs, factor-dominant profiles are defined by F_{AB} directionality correspondence with one factor (F_A dominant,

V and VI; F_B dominant, VII and VIII). Principal component analysis (Figure 2D) demonstrates that concordant EPs (I and II) were the most abundant in our dataset, followed by Pam2-dominant profiles (V and VI). This abundance of EPs I and II better emphasizes the cooperative effects of both factors than does conventional DEM clustering alone. In particular, the contribution of ODN to the synergistic combination might otherwise be overlooked by DEM analysis, as it induces enrichment of far fewer signaling pathways (Figure 2B) and has a greater clustering distance from Pam2-ODN samples (Figure 2C).

160

Notably, enrichment analysis reveals that molecular effectors clustered by EPs correspond with Pam2-ODN-induced functions (Figure 2E), suggesting a biological basis for the synergy. Specifically, we found that features in profiles I and V contributed to host survival functions, immune activity and microbicidal activity. Considered from an organizational perspective, induction of resistance to infection at the organismal level correlated with features in profile I, at the cellular level with profile II, and by leukocytes with profile V.

167

Factorial effects analysis integrates biological and statistical interactions in EPs

Analysis of factorial effects in a data matrix from single vs. dual factor exposures can statistically differentiate whether stochastic feature expression in a combination is correlated with the effect of an individual factor (simple main effect, SME) or their influence on each other (interaction effect) (Li *et al*, 2013; Mihret *et al*, 2014; Zhang *et al*, 2017). Based on this principle, OBIF performs full factorial analysis through paired comparisons of calculated β coefficients in each condition to determine statistical relationships (Hassall *et al*, 2018) and discover significant main effects during expression analysis and multi-factor effects (SMEs and interaction effect) from contrast (Mee, 2009) analysis (Figure 3A). Using this approach, main effects determined significant DEMs per condition, while multi-factor effects explained whether Pam2-ODN DEMs and EPs resulted from SMEs and/or an interaction of individual ligands (Figure 3B). This analysis showed that most features in concordant profiles (I and

II) are influenced by at least one multi-factor effect, while all features in discordant profiles (III and IV) are influenced by all multi-factor effects simultaneously. Not surprisingly, Pam2-dominant (V and VI) and ODN-dominant (VII and VIII) expression mainly results from their respective SMEs. This analysis also revealed that 67% (2116/3138) of Pam2-ODN DEMs are driven by the interaction effect of Pam2 and ODN as interacting DEMs (iDEMs) (Figure 3C). Thus, OBIF reconciled the biological interactions from EPs with the statistical interactions from multi-factor effects of Pam2-ODN.

SMEs accurately reproduce the regulatory network of combined exposures

Downstream analyses of SMEs have the capacity to discern the contributing roles of individual factors to a combination treatment (Hassall *et al*, 2018). Hence, Pam2-ODN DEMs with significant SMEs were used for network analysis of upstream regulators that are activated (orange) or inhibited (blue) and up-regulated (red) or down-regulated (green) (Figure 3D). Similar to our previous findings with DEMs (Figure 2B), transcription factors from many pathways were involved, though NF-κB family members remained central elements of this network. Demonstrating the cross-Omics function of OBIF, a parallel analysis of reverse-phase protein array (RPPA) data from single- or dual-treated human lung epithelial cells identified the top phospho-signaling DEMs (Figure EV2), and cross-validated STAT3, RelA and cJun as transcriptional units involved in the Pam2-ODN signaling network (Figure 3E).

iDEMs identify non-additive features and synergy regulators

Non-additivity results from strong interaction effects between two factors in a combination and gives rise to synergistic or antagonistic responses (Slinker *et al*, 1998; Geary *et al*, 2013). iDEMs integrate this principle during feature selection based on significant interaction effects between factors, allowing quantification of synergistic and antagonistic expression in a narrower set of differentially expressed features. OBIF builds on previous definitions of the combination index (CI) (Foucquier *et al*, 2015; Goldstein *et al*, 2017) to fit the values of feature expression:

$$CI = | (\text{Log}_2FC F_{AB}) / (\text{Log}_2FC F_A + \text{Log}_2FC F_B) |$$

where CI is the absolute ratio of the log2 fold change of Pam-ODN-induced DEMs (F_{AB}) and the additivity threshold of Pam2 (F_A) and ODN (F_B), allowing identification of both antagonistic ($CI < 1$) or synergistic ($CI > 1$) features (Figure 3F). A log2 transformation of the CI then yields an interaction score (IS) that quantifies the effect size of non-additive expression relative to the additivity threshold, and can be applied to both antagonistic ($IS < 0$) and synergistic ($IS > 0$) iDEMs (Figure 3G). This allows more focused enrichment analysis, in this case supporting NF- κ B/RelA and AP-1/cJun as key transcriptional upstream regulators of Pam2-ODN's interaction effect and synergistic expression (Figure 3H).

Experimental validation of molecular regulators of Pam2-ODN synergy

Prompted by the foregoing results, we tested whether RelA and cJun were biologically relevant synergy regulators of Pam2-ODN-induced epithelial resistance. The DNA-binding activity of NF- κ B and AP-1 subunits in isolated human bronchial epithelial cells (HBEC-3kt) after stimulation with Pam2-ODN confirmed that RelA and cJun activation was strongly increased after 15 minutes of treatment without significant contribution of other family members (Figure 4A, Figure EV3A). Indeed, RelA and cJun exhibited surprisingly similar activation kinetics after Pam2-ODN treatment, further supporting cooperation or coordination (Figure 4B). Investigating this co-activation of non-redundant transcriptional families, single-cell nuclear translocation of canonical p50/RelA and cFos/cJun dimers in HBEC-3kt was assessed by imaging flow cytometry. We found that all transcriptional subunits exhibited an increased nuclear translocation (similarity score > 2) after 15 minutes of Pam2-ODN treatment relative to the PBS-treated cells (Figure 4C). However, neither Pam2 nor ODN alone induced the same magnitude of nuclear translocation, whether assessed by similarity scores (Rd value) or by the percentage of translocated cells (Figure 4D) relative to PBS treated cells.

Discovery of novel NF- κ B and AP-1 cooperation required for antiviral protection

To differentiate transcriptional cooperation from coincidental transcription factor activation after Pam2-ODN treatment, we assessed the Pam2-ODN-induced nuclear co-translocation of NF- κ B and AP-1

complexes in the presence or absence of NF- κ B inhibitor IMD-0354 (IMD). As expected, pre-treatment with IMD alone reduced the Rd Value and percentage of translocated cells for RelA and p50 without significantly modifying the percentage of translocation for cJun and cFos. However, NF- κ B inhibition with IMD also unexpectedly reduced the Pam2-ODN-induced similarity score shifts and nuclear translocation of AP-1 subunits, particularly of cFos (Figure 4E). This indicates that NF- κ B inhibition impaired Pam2-ODN-induced AP-1 nuclear translocation, confirming the cooperative regulation of these two non-overlapping signaling pathways. Representative images shown in Figure 4F demonstrate that inhibition with IMD reduced Pam2-ODN-induced heterodimerization and nuclear translocation of NF- κ B and AP-1 complexes. Further, we confirmed that disruption of this transcriptional cooperation was sufficient to impair the inducible viral burden reduction seen with Pam2-ODN (Figure 4G).

Application of OBIF across multiple platforms and conditions

To demonstrate its generalizability, we used OBIF to analyze synergistic regulators in datasets derived from microarray, RNA-seq, RPPA and mass spectrometry-based metabolomics investigations of diverse factor classes and biological systems that demonstrate synergistic biological outcomes (Data Ref: Tuvim *et al*, 2014; Data Ref: Caetano *et al*, 2018; Data Ref: Singh *et al*, 2019; Data Ref: Han *et al*, 2019). As a preliminary step before full factorial analysis of individual features, OBIF performs an interaction analysis between the two factors of interest using a two-way ANOVA model to represent the impact of factorial effects at the whole “-ome” level. This statistical summary shows the effects of individual factors and interactions through interaction plots and statistical significance calculations (Figure 5A). This provides adjusted R^2 and F-statistic p-values of the two-way ANOVA that allow evaluation of improved model fitness (Figure EV4 A) and detection of interaction terms (Figure EV4 B) within a dataset. After confirming adequate model fitness (i.e. adjusted $R^2 > 0.5$, F-test < 0.05), full factorial analysis on scaled data from targeted or non-targeted platforms identifies DEMs (Figure 5B) from individual features with an increased discriminatory power for interaction effects (Figure EV4C).

EPs then represent the biological interactions of dual factor DEMs regardless of their factor classes (Figure 5C). Contrast analysis is then applied to more adequately retrieve and classify iDEMs (Figure EV4D) and interaction scores are calculated in a uniform scale whether the original data contained continuous or count-based expression values (Figure 5D). Finally, OBIF visually summarizes the results of full factorial analysis in a Circos plot to easily identify molecular drivers of synergy from the co-expressed features, DEMs, $\log_2FC$, EPs, multi-factor effects and iDEMs with their interaction score (Figure 5E).

Discussion

Synergistic and antagonistic interactions are common in nature and frequently promote efficacy of therapeutic interventions (Chen *et al*, 2015; Ronzitti *et al*, 2018; Wei *et al*, 2018; Zappasodi *et al*, 2018; Han *et al*, 2019). While synergy quantification methods from dose-response data, combinatorial screening of molecule libraries, and other predictive exploration models may suggest potentially synergistic conditions or treatments, they do not provide substantive insights into the molecular mechanisms underlying synergy (Chen *et al*, 2015). Thus, synergy-mediating pathways cannot be strategically targeted in rational drug development.

Our interest in synergy arose from our observations of the strikingly synergistic interactions of one such empirically derived combination, Pam2-ODN. While we could easily quantify the superiority of protection conferred by the dual treatment, in the absence of a systems theory to interrogate synergistic mechanisms (Chen *et al*, 2015; Wei *et al*, 2018), we were limited in our capacity to use available Omics datasets to deduce the mechanisms mediating the synergy. This is important because, although this lack of mechanistic understanding does not limit the utility of the current combination, it precludes development of next generation interventions that more precisely (perhaps, more efficaciously) target the synergy-driving pathways with fewer off-target (potentially toxic) effects. In contrast to models that predict possible synergy, OBIF was developed with the explicit intent to investigate established

283 synergistic events. As such, it is inherently a phenotype-driven model that performs full factorial
 284 analysis on feature expression data from single vs. dual factor exposures to identify molecular clusters
 285 that reveal synergy-mediating pathways, functions and regulators.

286

287 Using Pam2-ODN datasets as demonstrative examples, OBIF identified unanticipated transcriptional
 288 cooperation between non-redundant transcription factors, RelA and cJun, as a molecular mechanism of
 289 inducible synergistic protection against IAV. Thus, by facilitating understanding of combined factor
 290 exposures in terms of the individual components, a computational discovery facilitated experimental
 291 validation of a discrete, novel mediator of a non-additive biological response. Perhaps as importantly,
 292 the computational analyses were accomplished by integration of data from different Omics platforms,
 293 different specimen types, and even different host species.

294

295 Unlike most 2^2 designs, OBIF dissects factorial effects of dual factor exposures through full factorial
 296 analysis of feature expression data in a single unsupervised step. This allows simultaneous
 297 identification of DEMs directly from main effects of single or dual factors, overcoming pairwise
 298 comparisons to control and repetitive analysis of each condition. While this simultaneous identification
 299 of DEMs can be performed also with a mixed-effect model, we showed how this approach is suboptimal
 300 to detect interaction effects at the level of individual features and iDEM selection when compared with
 301 full factorial analysis. Additionally, clustering by DEMs, EPs and iDEMs improves the specificity of
 302 enrichment analysis to disentangle the signaling pathways, functions and regulators of this synergistic
 303 combination and to capture their specific driving features. Further, quantification of multi-factor effects
 304 (SMEs and interaction effects) reveals whether particular features, molecular clusters or functions
 305 enriched by synergistic combinations are the result of individual factors or their crosstalk.

306

307 These statistical relationships have biological analogues that are integrated by OBIF in the EP
 308 definitions. In fact, profiles I and II rescued the underrepresentation of ODN observed in distance-based

clustering and enrichment analysis. Further, iDEMs derived from features with significant interaction effects allow focusing discovery on synergy regulators and the calculation of interaction scores allows quantification of their non-additive expression. Thus, unlike most systems models of synergy, OBIF facilitates integrative analyses of biological and statistical interactions that are easily discoverable and interpretable through molecular clusters representing the complex dynamics of synergistic combinations.

OBIF is available as an open-source R package with a semi-automated pipeline to facilitate its broad application to unscaled original data from various Omics platforms, factor classes and biological systems. We have shown that OBIF can be fitted to perform full factorial analysis and that it adequately identifies DEMs, EPs, iDEMs and their attendant values and scores to promote discovery of molecular drivers of synergy in multiple, diverse datasets.

In summary, OBIF provides a phenotype-driven systems biology model that allows multiplatform dissection of molecular drivers of synergy. And, we encourage the application of OBIF to provide holistic understanding in research fields where greater-than-additive beneficial combinations remain understudied.

Materials and Methods

Reagents and Tools Table

Reagent/Resource	Reference or Source	Identifier or Catalog Number
Experimental Models		
C57BL/6J (M. musculus)	Jackson Lab	B6.129P2Gpr37tm1Dgen/J
Immortalized human bronchial epithelial (HBEC-3kt) cells	Dr. John Minna	Authenticated by the MD Anderson Characterized Cell Line Core Facility
Murine lung epithelial (MLE-15) cells	Dr. Jeffrey Whitsett	Authenticated by the MD Anderson Characterized Cell Line Core Facility
Antibodies		

NFκB p50 (E-10) Alexa Fluor® 647	Santa Cruz Biotechnology, Inc.	Cat # sc-8414 AF647
NFκB p65 (F-6) Alexa Fluor® 488	Santa Cruz Biotechnology, Inc.	Cat # sc-8008 AF488
c-Jun (G-4) Alexa Fluor® 594	Santa Cruz Biotechnology, Inc.	Cat # sc-74543 AF594
c-Fos Antibody (D-1) Alexa Fluor® 546	Santa Cruz Biotechnology, Inc.	Cat # sc-8047 AF546
Oligonucleotides and sequence-based reagents		
Mouse 18s - Forward Primer	Sigma-Aldrich	5'-CTCATCCTTTATGACAAAGAAG-3'
Mouse 18s - Reverse Primer	Sigma-Aldrich	5'-AGATCATCATGTGAGTCAGAC-3'
Influenza NP - Forward Primer	Sigma-Aldrich	5'-GTAACCCGTTGAACCCCAT-3'
Influenza NP - Reverse Primer	Sigma-Aldrich	5'-CCATCCAATCGGTAGTAGCG-3'
Chemicals, enzymes and other reagents		
eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set	Thermo Fisher Scientific	Cat # 00-5523-00
LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit	Thermo Fisher Scientific	Cat # L34975
Power SYBR Green PCR Master Mix	Thermo Fisher Scientific	Cat # 4368702
UltraComp eBeads™ Compensation Beads	Thermo Fisher Scientific	Cat # 01-2222-42
RNAlater	Sigma-Aldrich	Cat # R0901-500ML
Accutase solution	Sigma-Aldrich	Cat # A6964-500ML
IMD-0354	Sigma-Aldrich	Cat # I3159-5MG
iScript™ cDNA Synthesis Kit	Bio-Rad	Cat # 1708891BUN
Software		
Rstudio	RStudio, Inc.	Version 1.2.5033
R	www.R-project.org	Version 3.6.3
Prism 8	GraphPad Software, LLC.	Version 8.4.2
Amnis® IDEAS®	Luminex Corporation	Version 6.1
INSPIRE ImageStreamX	Luminex Corporation	System Version
KCJunior	Bio-Tek Instruments, Inc.	System Version
CFX Maestro™ Software	Bio-Rad	Cat # #12004110
Other		
TransAM NFκB Family	Active Motif	Cat # 43296
TransAM AP-1 Family	Active Motif	Cat # 44296

TransAM STAT Family	Active Motif	Cat # 42296
RNeasy Mini Kit	Qiagen	Cat # 74106
QIAshredder	Qiagen	Cat # 79656
CFX Connect Real-Time PCR Detection System	Bio-Rad	Cat # 1855201
uQuant Universal Microplate Spectrophotometer	Bio-Tek Instruments, Inc.	Cat # MQX200
TProfessional TRIO combi PCR Thermocycler	Biometra	Cat # 070-724
NanoDrop™	Thermo Fisher Scientific	Cat # ND-ONE-W
One Microvolume UV-Vis Spectrophotometer		
Amnis®	Luminex Corporation	Serial # ISX325
ImageStream®XMk II		

329

330 **Methods and Protocols**

331 **Experimental Models**

332 *Animals*

333 All mouse experiments were performed with 6-10 week old C57BL/6J mice of a single sex in
334 accordance with the Institutional Animal Care and Use of Committee of The University of Texas MD
335 Anderson Cancer Center, protocol 00000907-RN01.

336

337 *Cell culture*

338 Immortalized human bronchial epithelial (HBEC-3kt) cells were kindly provided by Dr. John Minna.
339 HBEC-3kt cells were cultured in keratinocyte serum-free media (KSFM) supplemented with human
340 epidermal growth factor and bovine pituitary extract. Murine lung epithelial (MLE-15) cells were kindly
341 provided by Dr. Jeffrey Whitsett. The cell lines used were authenticated by the MD Anderson
342 Characterized Cell Line Core Facility. MLE-15 cells were cultured in RPMI supplemented with 10% fetal
343 bovine serum. Cultures were maintained in the presence of penicillin and streptomycin.

344

345 **Exposure to TLR ligands**

S-[2,3-bis(palmitoyloxy)-propyl]-(R)-cysteinyl-(lysyl) 3-lysine (Pam2 CSK4) and ODN M362 were reconstituted in endotoxin-free water, then diluted to the desired concentration in sterile PBS. For in vivo experiments, as previously described (Kirkpatrick et al, 2018; Ware et al, 2019), the indicated ligands were placed in an Aerotech II nebulizer driven by 10L/min air supplemented with 5% CO₂ for 20 min. The nebulizer was connected by polyethylene tubing to a polyethylene exposure chamber. 24 h prior to infections, 10 ml of Pam2 (4 µM) and/or ODN (1 µM) was delivered via nebulization to unrestrained mice for 20 minutes, and then mice were returned to normal housing. For in vitro experiments, Pam2-ODN was added to the culture media 4 h prior to inoculation with virus.

Reverse-Phase Protein Array

To simultaneously evaluate the expression of 161 regulatory proteins and phospho-proteins in HBEC-3kt cells after exposure to either PBS, Pam2, ODN or Pam2-ODN, a targeted high-throughput screening proteomic assay was performed by the Reverse Phase Protein Array Core Facility at The University of Texas MD Anderson Cancer Center (Tibes et al, 2006; Hennessy et al, 2010). The RPPA included 4 biological replicates per treatment condition, and data is available at GitHub (www.github.com/evanslaboratory/OBIF).

Infection Models

For in vivo infections, frozen stock (2.8×10^7 50% tissue culture infective doses [TCID₅₀] ml⁻¹) of influenza A H3N2, virus was diluted 1:250 in 0.05% gelatin in Eagle's minimal essential medium and delivered by aerosolization for 20 min to achieve a 90% lethal dose (LD₉₀) to LD₁₀₀ (~100 TCID₅₀ per mouse). Mouse health was followed for 21 d post infection. n = 15 mice per condition. Animals were weighed daily and sacrificed if they met euthanasia criteria, including signs of distress or loss of 20% pre-infection body weight. For in vitro infections, IAV (multiplicity of infection [MOI] of 1.0) was added to cells in submerged monolayer and viral burden was assessed 24 hours post infection.

Pathogen burden quantification

To measure transcript levels of IAV nucleoprotein (NP) gene, samples were harvested in RNAlater and RNA was extracted using the RNeasy extraction kit. 500 ng total RNA was reverse transcribed to cDNA by using an iScript cDNA synthesis kit and submitted to quantitative reverse transcription-PCR (RT-PCR) analysis with SYBR green PCR master mix on an Bio-Rad CFX Connect Real-Time PCR Detection System. Host 18S rRNA was similarly probed to determine relative expression of viral transcripts.

Omics Dataset Formatting

OBIF's input in R requires an analysis-ready data matrix m with expression values and of dimensions $f \times n$, where f is the number of features as rows and n is the number of samples S as columns. The appropriate sample order in dimensions n of m is:

$$n = S_{(0,0)}^1 + \dots + S_{(0,0)}^i + S_{(1,0)}^1 + \dots + S_{(1,0)}^i + S_{(0,1)}^1 + \dots + S_{(0,1)}^i + S_{(1,1)}^1 + \dots + S_{(1,1)}^i$$

The subscripts denote the condition of the samples: exposed to neither factor (0,0), exposed to factor A alone (1,0), exposed to factor B alone (0,1) or exposed to both factors A and B (1,1). The superscripts represent the sample replicates from 1 to i within each of the four conditions.

To improve detection of interaction effects, OBIF allows sequential transformation of an unscaled original data matrix with background correction, log2-transformation, quantile normalization or a combination of these if needed. Background correction reduces noise to signal ratio at the lower limits of detection and methods vary per platform with code extensions are available at GitHub for microarray data using the lumi package, and for count-based sequencing data using rpm, rpkm, fpkm and tpm thresholds. Log2-transformation of continuous and count-base data is incorporated to provide a Gaussian-like data distribution, and quantile normalization is used to minimize the variance between samples during data scaling (Lo *et al*, 2015; Abrams *et al*, 2019) with OBIF to meet the statistical

assumptions needed for two-way ANOVA analysis of interaction terms in a dataset (Slinker, 1998; Fouquier *et al*, 2015).

399

400 Interaction analysis

401 To evaluate significant interaction terms between factors at the whole “-ome” level, OBIF performs a
402 multiple linear regression across the expression values in a dataset:

$$403 \quad E_O \sim 0 + F_A + F_B + F_A \cdot F_B$$

404 where the interaction analysis of the Omics expression levels (E_O) is equivalent to a two-way ANOVA
405 analysis where the intercept is referenced to the control samples (0) and returns a statistical summary
406 of terms for the individual factor A (F_A), factor B (F_B) and their interaction ($F_A \cdot F_B$). Goodness of fit is
407 calculated from the adjusted R^2 values, and overall significance is determined by the p-values of F-
408 statistics of the regression. Unscaled original data and scaled data with OBIF are compared to evaluate
409 improvement in detection of significant interaction terms in a given dataset.

410

411 Full Factorial Analysis

412 Expression Analysis

413 To perform differential expression analysis for detection of DEMs, OBIF fits a fixed-effects model to the
414 expression data of each feature:

$$415 \quad E_f = \beta_0 + \beta_1 \cdot F_A + \beta_2 \cdot F_B + \beta_3 \cdot F_{AB}$$

416 where the expression level of features (E_f) is a function of the estimated β coefficients for the main
417 effects of individual factor A (F_A) and factor B (F_B) and their combination (F_{AB}). After regression,
418 empirical Bayesian shrinkage of the standard errors is used to stabilize inferences of t-statistics, F-
419 statistics, and log-odds used for differential expression analysis. Q-values are then calculated using the
420 Benjamini and Hochberg method to reduce the false discovery rate (FDR). Alternatively, code
421 extensions for are available at GitHub to perform Bonferroni corrections or calculate Tukey Honest
422 Significant Differences adjustment for multiple testing instead of FDR.

423

424 *Contrast analysis*

425 To analyze the remaining factorial effects in the fitted linear model of feature expression, the
426 coefficients and standard errors will be estimated typical of a two-way ANOVA from a set of contrasts
427 that define the SMEs of each factor and their interaction effect:

$$428 \text{SME of } F_A = \beta_3 \cdot F_{AB} - \beta_2 \cdot F_B$$

$$429 \text{SME of } F_B = \beta_3 \cdot F_{AB} - \beta_1 \cdot F_A$$

$$430 \text{Interaction effect of } F_A \cdot F_B (\beta_4) = \beta_3 \cdot F_{AB} - \beta_2 \cdot F_B - \beta_1 \cdot F_A$$

431 The standard errors calculated use a significance threshold (p-value < 0.05) to determine if DEMs with
432 F_{AB} (Pam2-ODN) are susceptible to SME or interaction effects. Selection of iDEMs is based on DEMs
433 of F_{AB} with a significant interaction effect.

434

435 **Mixed-effects model**

436 To evaluate performance of full factorial analysis with OBIF, detection of interaction effects at the level
437 of individual features is compared to a mixed-effect model (Caetano *et al*, 2018):

$$438 E_{f-Mix} = \beta_0 + \beta_1 \cdot F_A + \beta_2 \cdot F_B + \beta_4 \cdot F_A \cdot F_B + (1|S)$$

439 where the expression level of features in a mixed-effect model (E_{f-Mix}) is a function of the estimated β
440 coefficients for the fixed effects of individual factor A (F_A) and factor B (F_B) and their interaction ($F_A \cdot F_B$)
441 with a random effect (1|S) for all sample conditions ($S_{(0,0)}$, $S_{(1,0)}$, $S_{(0,1)}$, $S_{(1,1)}$). After regression, empirical
442 Bayesian shrinkage of the standard errors is used to stabilize inferences of t-statistics and F-statistics.
443 The standard errors calculated from the interaction term use a significance threshold (p-value < 0.05) to
444 determine significant interaction effects.

445

446 **Beta-uniform mixture model**

447 Interaction p-values are extracted from the interaction term of mixed-effects model and from the
448 interaction effect contrast of full factorial analysis. Independently, a beta-uniform mixture model is fitted

to these sets of p-values (Pounds *et al*, 2003; Ji *et al*, 2005) to compare their discrimination ability using their receiver operating characteristic area under the curve (ROC AUC). Using the beta-uniform mixture models, we calculated the number of true positives (TP), false positive (FP) and false negatives (FN) detections (Pounds *et al*, 2003; Zhang *et al*, 2012) at the threshold level of iDEM selection (interaction p-value = 0.05) to estimate their precision and recall proportion:

$$Precision = TP / (TP + FP)$$

$$Recall = TP / (TP + FN)$$

Unsupervised clustering of features with OBIF

Hierarchical clustering and heatmaps of DEMs

All DEMs were represented in heatmaps after hierarchically clustering using Ward's minimum variance method with Euclidean distances of $\log_2$ FC values to compute dissimilarity by rows (features) and by columns (samples). Column dendrograms were plotted to represent the distance between samples, vertical side bar colors summarize DEMs according to their and horizontal side bars colors represent sample types by factors. Color scale keys indicate the levels of feature expression with upregulation in red and downregulation in green.

Principal component analysis of expression profiles

DEMs with F_{AB} (Pam2-ODN) were clustered by principal component analysis based on the mean linear fold change difference to reveal the expression patterns biologically present across all factors FA, FB and FAB. Principal components 1 and 2 were used for plotting DEMs with FAB and the variability between features is marked in each axis. EPs were identified in the clusters for each individual feature according to Table 1.

Enrichment analysis

To provide biological interpretation of the full factorial analysis and classification of features, enrichment analysis was integrated in the pipeline to determine candidate effectors and regulators of synergy, biological pathways and functional processes. Sets for DEMs, EPs, DEMs with SMEs and iDEMs are uploaded independently, and enrichment analysis is performed with IPA software (QIAGEN, Hilden, Germany) for core analysis using the expression levels of features. Both gene and chemical Ingenuity Knowledge Base modules are used as enrichment reference, considering only experimentally observed confidence levels for identification of direct and indirect relationships. The thresholds of significance for canonical pathways, upstream analysis, diseases & functions, regulator effects and network analysis are ≥ 2 for activation z-score and $< 5\%$ false discovery rates for all predictions.

DNA-binding ELISA

HBEC-3kt were grown to 80-100% confluence in 24-well plates and treated with PBS, Pam2, ODN, or Pam2-ODN for the indicated durations. Measurements of DNA-binding of members of NF- κ B and AP-1 transcription factor members from whole cell lysates were made using their respective TransAM Kit according to product directions. For signal detection, samples were read immediately for absorbance at 450 nm with reference wavelength at 655 nm on a microplate reader. Experiments were repeated in triplicate and statistical analysis was performed with unpaired student's t test using GraphPad Prism 8.0 with a significance threshold of p-value < 0.05 .

Detection of Nuclear Translocation

Transcription factor staining and image acquisition

HBEC-3kt were grown to 80-100% confluence in 100mm dishes and treated for 30 min with PBS, Pam2, ODN or Pam2-ODN with or without pretreatment with NF- κ B inhibitor IMD-0354 at 25 ng/ μ L for 16 h. Cells were detached from the plate with a 5 min incubation at 37 °C degrees with 3 ml of Accutase to prevent additional activation of transcriptional activity. Cells were pelleted in individual 15 ml tubes at 500 g for 5 min and suspended in 500 μ L of eBioscience FOXP3 fixation/permeabilization

500 buffer for 15 min at room temperature. Cells were stained with a LIVE/DEAD Fixable Near IR Dead Cell
501 Dye and with a 1:1000 dilution of NF- κ B p50 (E-10) Alexa Fluor 647, NF- κ B p65 (F-6) Alexa Fluor 488,
502 c-Jun (G-4) Alexa Fluor 594 and c-Fos (D-1) Alexa Fluor 546 conjugated antibodies for 1 h on ice and
503 protected from light. After incubation, cells were pelleted and washed with 200 μ L of sterile PBS 4
504 times, then resuspended in 100 μ L sterile PBS. After the last wash, cells were pelleted and
505 resuspended in 50 μ L of sterile PBS and nuclear DAPI staining at 0.5 μ g/mL was performed just prior to
506 data acquisition on ImageStreamX MII.

507

508 *Data acquisition with ImageStreamX MKII*

509 HBEC-3kt images were acquired using INSPIRE software on the ImagestreamX Mark II imaging flow
510 cytometer (Amnis Corporation) at 40 $\times$ magnification, with lasers 405 nm (85.00 mW), 488 nm
511 (200.00 mW), and side scatter (782 nm) (1.14 mW). 10,000 images per sample acquired include a
512 brightfield image (Channel 1 and 9), p65 Alexa Fluor 488 (Channel 2), c-Fos Alexa Fluor 546 (Channel
513 3), c-Fos Alexa Fluor 594 (Channel 4), side scatter (Channel 6), DAPI (Channel 7), and p50 Alexa Fluor
514 647 (Channel 3). The laser outputs prevented saturation of pixels in the relevant detection channels as
515 monitored by the corresponding Raw Max Pixel features during acquisition. For image compensation,
516 single color controls were stained with all fluorochromes and 500 events were recorded with each laser
517 for individual controls. Fluorescent images were taken in all channels with brightfield LEDs and scatter
518 lasers turned off to accurately capture fluorescence. Individual single-color control file was then merged
519 to generate a compensation matrix and all sample files were processed with this matrix applied.

520

521 *Nuclear translocation analysis*

522 After compensation for spectral overlap based on single color controls, analysis was performed and
523 individual cell images were created using IDEAS® software version 6.1. Cell populations were
524 hierarchically gated first by single cells, then cells in focus, then negative selected for live cells, and
525 finally as double positive for both DAPI and the transcription factor subunit of interest (Figure EV3B).

The spatial relationship between the transcription factors and nuclear images was measured using the 'Similarity' feature in the IDEAS software to quantitate the mean similarity score in the cell populations per sample. A similarity score >1 represents nuclear translocation, and the shift in distribution of nuclear translocation between two samples was calculated using the Fisher's Discriminant ratio (Rd value) (Maguire *et al*, 2015).

Statistical Analysis

Statistical analyses were performed using Prism 8 (GraphPad, San Diego, CA) and R. Kaplan-Meier curves were used for survival analyses and logrank (Mantel-Cox test) was used for paired group comparisons. Analysis of viral NP expression was performed using a two-way ANOVA with post hoc Tukey analysis for paired comparisons that was adjusted for multiple testing. Analysis of DNA-binding activity *in vitro* was performed using a student's t test for comparisons between 2 groups, or using one-way ANOVA for comparison between multiple groups. Grouped data is shown as means +/- standard error of the mean, with experiments with $n < 5$ showing individual sample values. To verify the statistical assumptions for each test, Gaussian distribution was evaluated with Saphiro-Wilk test, and equal variance between two samples was evaluated with F-tests, or for more than two samples with Barlett's or Levene's test. Simultaneous multiple outlier detection was performed using the robust regression and outlier removal (ROUT) method with a q value of 5% (maximum FDR). Treatment allocation of animals was randomized in the experiments, though assessment could not be blinded. A pre-specified minimum requirement of 3 biological replicates for *in vitro* studies and 10 for *in vivo* studies.

Data Availability

The data and code in this study are available in the following databases:

- OBIF R Package: GitHub Evanslaboratory/OBIF ([www.github.com/evanslaboratory/OBIF](https://github.com/evanslaboratory/OBIF))
- OBIF R Code: GitHub Evanslaboratory/Extensions ([www.github.com/evanslaboratory/Extensions](https://github.com/evanslaboratory/Extensions))

- 552 • Microarray data: Gene Expression Omnibus GSE28994
- 553 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28994>)
- 554 • RNA-seq data: Gene Expression Omnibus GSE109000
- 555 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109000>)
- 556 • Reverse-phase protein array data: GitHub Evanslaboratory/Datasource
- 557 (www.github.com/evanslaboratory/Datasource)
- 558 • Reverse-phase protein array data: EMBO Molecular Medicine DOI:10.15252/emmm.201809960
- 559 (<https://www.embopress.org/doi/abs/10.15252/emmm.201809960>)
- 560 • Metabolomics data: Frontiers in Pharmacology DOI:10.3389/fphar.2019.00754
- 561 (<https://www.frontiersin.org/articles/10.3389/fphar.2019.00754/full>)

562

563 **Acknowledgements**

564 The research reported here was supported by The University of Texas System and Mexico's Consejo
 565 Nacional de Ciencia Y Tecnología (CONACYT) through the ConTex Postdoctoral Fellowship Program
 566 to J.P.G., by NIH grants R01 HL117976, DP2 HL123229 and R35 HL144805 to S.E.E. and by
 567 P30CA016672 to MD Anderson Cancer Center. The opinions expressed are those of the authors and
 568 do not represent views of these funding agencies. The Functional Proteomics RPPA Core facility is
 569 supported by MD Anderson Cancer Center Support Grant # 5 P30 CA016672-40. The Advanced
 570 Cytometry & Sorting Core Facility is supported by NCI P30CA016672 and is equipped for Imaging Flow
 571 Cytometry at MD Anderson Cancer Center. J.P.G. acknowledges and thanks the Methods in
 572 Epidemiologic, Clinical and Operations Research (MECOR) Program from the American Thoracic
 573 Society (ATS) and Asociación Latinoamericana de Tórax (ALAT) for their support and dedication in
 574 building research capacity in Latin America and other countries around the globe, particularly to their
 575 faculty Dr. Fernando Holguin and Dr. Altay Souza for their critical feedback.

576

577 **Author contributions**

578 Conforming to the ICMJE criteria, all authors gave approval of the final version to be published and
 579 contributed to writing or revising the article critically for important intellectual content. Conforming to the
 580 CRediT criteria: J.P.G. and S.E.E. were involved in conceptualization of the project, visualization and
 581 writing of original draft, review & editing, and funding acquisition; J.P.G. was involved in data curation,
 582 formal analysis and methodology by conceiving, implementing and validating the systems model;
 583 J.P.G., V.V.K., T.C.R. and S.J.W. were involved in investigation by performing in vitro and in vivo
 584 experiments; J.P.G., V.V.K., T.C.R., S.W., S.J.W., J.Z., J.W., Y.W. and S.E.E. were involved in
 585 supervision by interpreting results; S.W., R.S., M.S.C., S.J.M., and F.M.J. were involved in providing
 586 resources by generating datasets for analysis and validation of the model; J.P.G., J.Z. and J.W. were
 587 involved in formal analysis, software and validation by performing bioinformatics analyses; Y.W. and
 588 S.E.E. were involved in supervision, project administration and validation of the project.

589

590 **Conflict of interest**

591 S.E.E. is an author on U.S. patent 8,883,174 “Stimulation of Innate Resistance of the Lungs to Infection
 592 with Synthetic Ligands” and owns stock in Pulmotect Inc., which holds the commercial options on these
 593 patent disclosures. All other authors declare that no conflict of interest exists.

594

595 **References**

- 596 Abrams ZB, Johnson TS, Huang K, Payne PRO, Coombes K (2019) A protocol to evaluate RNA
 597 sequencing normalization methods. *BMC Bioinformatics*, 20(Suppl 24), 679
- 598 Antony J (2014). 6 - Full Factorial Designs. In *Design of Experiments for Engineers and Scientists*,
 599 Antony J (ed) pp 63-85. Oxford: Elsevier
- 600 Bardini R, Politano G, Benso A, Di Carlo S (2017) Multi-level and hybrid modelling approaches for
 601 systems biology. *Computational and Structural Biotechnology Journal*, 15, 396-402

602 Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H,
603 Deng S, Diao L, *et al* (2018) Sex specific function of epithelial STAT3 signaling in pathogenesis of K-
604 ras mutant lung cancer. *Nature communications*, 9(1), 4589

605 Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H,
606 Deng S, Diao L, *et al* (2018) Gene Expression Omnibus GSE109000
607 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109000>) [DATASET]

608 Chen D, Liu X, Yang Y, Yang H, Lu P (2015) Systematic synergy modeling: understanding drug
609 synergy from a systems biology perspective. *BMC Syst Biol*, 9, 56

610 Cleaver JO, You D, Michaud DR, Pruneda FA, Juarez MM, Zhang J, Weill PM, Adachi R, Gong L,
611 Moghaddam SJ, *et al* (2014) Lung epithelial cells are essential effectors of inducible resistance to
612 pneumonia. *Mucosal Immunol*, 7(1), 78-88

613 Collaborators GL (2017) Estimates of the global, regional, and national morbidity, mortality, and
614 aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global
615 Burden of Disease Study 2015. *The Lancet. Infectious diseases*, 17(11), 1133-1161

616 Coral C, Bokelmann W (2017) The Role of Analytical Frameworks for Systemic Research Design,
617 Explained in the Analysis of Drivers and Dynamics of Historic Land-Use Changes. *Systems*, 5(1)

618 Das AK, Dewanjee S (2018) Chapter 3 - Optimization of Extraction Using Mathematical Models and
619 Computation. In *Computational Phytochemistry*, Sarker SD, Nahar L (ed) pp 75-106. Elsevier.

620 Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzman Pruneda FA, Tuvim MJ, Zhang J,
621 Dickey BF, Evans SE (2011) Synergistic interactions of TLR2/6 and TLR9 induce a high level of
622 resistance to lung infection in mice. *J Immunol*, 186(10), 5916-5926

623 Fouquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape.
624 *Pharmacol Res Perspect*, 3(3), e00149

625 Geary N (2012) Understanding synergy. *American Journal of Physiology-Endocrinology and*
626 *Metabolism*, 304(3), E237-E253

627 Goldstein I, Paakinaho V, Baek S, Sung MH, Hager GL (2017) Synergistic gene expression during the
628 acute phase response is characterized by transcription factor assisted loading. *Nature*
629 *Communications*, 8(1), 1849

630 Han ML, Liu X, Velkov T, Lin YW, Zhu Y, Creek DJ, Barlow CK, Yu HH, Zhou Z, Zhang J, *et al* (2019)
631 Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin
632 and Sulbactam Combination Against Multidrug-Resistant *Acinetobacter baumannii*. *Frontiers in*
633 *Pharmacology*, 10(754)

634 Han ML, Liu X, Velkov T, Lin YW, Zhu Y, Creek DJ, Barlow CK, Yu HH, Zhou Z, Zhang J, *et al* (2019)
635 *Frontiers in Pharmacology* DOI:10.3389/fphar.2019.00754
636 (<https://www.frontiersin.org/articles/10.3389/fphar.2019.00754/full>) [DATASET]

637 Hasin Y, Seldin M, Lusi A (2017) Multi-omics approaches to disease. *Genome Biol*, 18(1), 83

638 Hassall KL, Mead A (2018) Beyond the one-way ANOVA for 'omics data. *BMC Bioinformatics*, 19(Suppl
639 7), 199

640 Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K,
641 Meric-Bernstam F, *et al* (2010) A Technical Assessment of the Utility of Reverse Phase Protein
642 Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.
643 *Clinical proteomics*, 6(4), 129–151

644 Kirkpatrick CT, Wang Y, Leiva Juarez MM, Shivshankar P, Pantaleon Garcia J, Plumer AK, Kulkarni V,
645 Ware H, Martinez Zayas, G, Wali S, *et al* (2018) Inducible Lung Epithelial Resistance Requires
646 Multisource Reactive Oxygen Species Generation To Protect against Viral Infections. *MBio*, 9(3)

647 Li C, Shen W, Shen S, Ai Z (2013) Gene expression patterns combined with bioinformatics analysis
648 identify genes associated with cholangiocarcinoma. *Comput Biol Chem*, 47, 192-197

649 Li OTW, Chan MCW, Leung CSW, Chan RWY, Guan Y, Nicholls JM, Poon LLM (2009) Full factorial
650 analysis of mammalian and avian influenza polymerase subunits suggests a role of an efficient
651 polymerase for virus adaptation. *PLOS ONE*, 4(5), e5658-e5658

652 Lo S, Andrews S (2015) To transform or not to transform: using generalized linear mixed models to
653 analyse reaction time data. *Front Psychol*, 6, 1171

654 Maguire O, O'Loughlin K, Minderman H (2015) Simultaneous assessment of NF- κ B/p65
655 phosphorylation and nuclear localization using imaging flow cytometry. *Journal of immunological*
656 *methods*, 423, 3-11

657 Mee RW (2009) Analysis of Full Factorial Experiments. In *A Comprehensive Guide to Factorial Two-*
658 *Level Experimentation*, R. Mee (ed) pp 27-74. New York, NY: Springer New York

659 Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ,
660 Flanders SA, *et al* (2019) Diagnosis and Treatment of Adults with Community-acquired Pneumonia.
661 An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases
662 Society of America. *American journal of respiratory and critical care medicine*, 200(7), e45-e67

663 Mihret A, Loxton AG, Bekele Y, Kaufmann SHE, Kidd M, Haks MC, Ottenhoff THM, Aseffa A, Howe R,
664 Walzl G (2014) Combination of gene expression patterns in whole blood discriminate between
665 tuberculosis infection states. *BMC Infectious Diseases*, 14(1), 257

666 Ronzitti G, Mingozzi F (2018) Combination Therapy Is the New Gene Therapy? *Molecular therapy : the*
667 *journal of the American Society of Gene Therapy*, 26(1), 12-14

668 Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM (2019)
669 Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. *EMBO*
670 *Molecular Medicine*, 11(5), e9960

671 Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM (2019)
672 EMBO Molecular Medicine DOI:10.15252/emmm.201809960
673 (<https://www.embopress.org/doi/full/10.15252/emmm.201809960>) [DATASET]

674 Slinker BK (1998) The statistics of synergism. *Journal of molecular and cellular cardiology*, 30(4), 723-
675 731

676 Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM (2006) Reverse phase protein
677 array: validation of a novel proteomic technology and utility for analysis of primary leukemia
678 specimens and hematopoietic stem cells. *Molecular cancer therapeutics*, 5(10), 2512–2521

679 Tuvim MJ, Gilbert BE, Dickey BF, Evans SE (2012) Synergistic TLR2/6 and TLR9 activation protects
680 mice against lethal influenza pneumonia. *PLOS ONE*, 7(1), e30596-e30596

681 Tuvim MJ, Gilbert BE, Dickey BF, Evans SE (2012) Gene Expression Omnibus GSE28994
682 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28994>) [DATASET]

683 Ware HH, Kulkarni VV, Wang Y, Pantaleón García J, Leiva Juarez M, Kirkpatrick CT, Wali S, Syed S,
684 Kontoyiannis AD, Sikkema WK, *et al* (2019) Inducible lung epithelial resistance requires multisource
685 reactive oxygen species generation to protect against bacterial infections. *PLOS ONE*, 14(2),
686 e0208216

687 Wei PL, Gu H, Liu J, Wang Z (2018) Development of Fangjiomics for Systems Elucidation of
688 Synergistic Mechanism Underlying Combination Therapy. *Comput Struct Biotechnol J*, 16, 565-572

689 Zappasodi R, Merghoub T, Wolchok JD (2018) Emerging Concepts for Immune Checkpoint Blockade-
690 Based Combination Therapies. *Cancer Cell*, 34(4), 690

691 Zhang J, Coombes KR (2012) Sources of variation in false discovery rate estimation include sample
692 size, correlation, and inherent differences between groups. *BMC Bioinformatics*, 13 Suppl 13, S1

693 Zhang X, Cha IH, Kim KY (2017) Use of a Combined Gene Expression Profile in Implementing a Drug
694 Sensitivity Predictive Model for Breast Cancer. *Cancer Res Treat*, 49(1), 116-128

695 **Figure legends**

696

697 **Figure 1. Omics-Based Interaction Framework: phenotype-driven synergy modeling and** 698 **framework overview.**

699 (A) Mouse survival of influenza A challenge following the indicated pretreatments. Dashed line indicates
700 additive effect of single ligand treatments over PBS. $n = 15$ mice/condition. (B) Virus burden of isolated
701 mouse lung epithelial cells after influenza A challenge following the indicated pretreatments. RQ,
702 relative quantification of viral nucleoprotein (NP) expression to host 18s. $n = 6$ samples/condition. (C)
703 Plot of response additivity from antiviral responses in panels A (left) and B (right). Synergistic effects
704 are reflected by E_{AB} greater than the expected linear sum ($E_A + E_B$, dashed line) of individual ligand
705 effects, antagonistic effects are observed when $E_{AB} < E_A + E_B$. (D) Generic Omics workflow for
706 phenotype-driven synergy modeling using a 22 experimental design. (E) Overview of OBIF, including (i)
707 Omics screening of features in a data matrix, (ii) discovery of feature clusters of molecular drivers, and
708 (iii) experimental validation of biologically relevant synergy regulators. * $P < 0.05$ compared to either
709 condition, *** $P < 0.0005$ compared to either condition.

710

711 **Figure 2. Differentially expressed molecules and expression profiles reveal synergy-mediating** 712 **pathways and functions.**

713 (A) Euler diagram of differentially expressed molecules following single or dual treatment in mouse lung
714 homogenates. (B) Most overrepresented activated canonical pathways after IPA enrichment of DEMs.
715 (C) Heatmap of expression values of DEMs in A with expression profiles shown per feature (rows). (D)
716 Principal component analysis of Pam2-ODN DEMs identified by expression profiles. (E) Top activated
717 (orange) and inhibited (blue) diseases and functions after IPA enrichment of expression profiles. FC,
718 fold change.

719

720 **Figure 3. Full factorial analysis reveals regulatory networks and molecular drivers of synergy.**

721 (A) Scheme of full factorial analysis performed by OBIF from β coefficients. (B) Venn diagram of Pam2-
722 ODN DEMs correlated by expression profiles classes and multi-factor effects. (C) Feature count and
723 percentage of Pam2-ODN iDEMs and non-iDEMs in B. (D) Network analysis of activated (orange) or
724 inhibited (blue), and up-regulated (red) or down-regulated (green) upstream regulators of Pam2-ODN
725 after IPA enrichment of SME. (E) Cross-Omics validation of regulators in D. Differentially expressed
726 phospho-signaling molecules were identified with OBIF from a reverse-phase protein array in human
727 lung epithelial cells. (F) Non-additive feature expression assessed by combination index (CI).
728 Representative genes and their CI values are shown. (G) Interaction score (IS) of iDEMs, reflecting
729 antagonistic (IS < 0) and synergistic (IS > 0) features. (H) Top activated (orange) or inhibited (blue)
730 transcriptional regulators after IPA enrichment of iDEMs. DEMs, differentially expressed molecules.
731 iDEMs, interacting DEMs. SME, simple-main effects.

732

733 **Figure 4. Regulators identified with OBIF uncovered cooperation between RelA and cJun that is**
734 **required for synergistic antiviral protection.**

735 (A) Transcription factor activity of NF- κ B and AP-1 subunits 15 min after treatment of human lung
736 epithelial cells with Pam2-ODN. n = 3-6 samples/condition. (B) RelA and cJun activity at indicated times
737 after Pam2-ODN treatment. n = 6 samples/condition. (C) Nuclear translocation scores of NF- κ B and
738 AP-1 heterodimers after Pam2-ODN treatment. Shown as normalized frequency of similarity score per
739 condition. (D) NF- κ B and AP-1 subunit nuclear translocation in C (increased, red; decreased, blue) per
740 condition. (E) NF- κ B and AP-1 subunit nuclear translocation with or without NF- κ B inhibition by IMD-
741 0345. (F) Representative imaging flow cytometry images of hetero-dimerization and nuclear
742 translocation of NF- κ B and AP-1 in D and E. (G) Virus burden of mouse lung epithelial cells challenged
743 with influenza A with or without NF- κ B inhibition. n = 4 samples/condition. *, P < 0.05; **, P < 0.005; ***,
744 P < 0.0005 compared to baseline.

745

746 **Figure 5. OBIF reveals molecular drivers of synergy across platforms, factor classes and**
 747 **experimental systems.**

748 (A) Interaction analysis of factorial effects at the whole “-ome” level, demonstrating interaction plots,
 749 coefficient significance and quality of model fitness per platform. (B) Euler diagram of DEMs identified
 750 in A. (C) Principal component analysis of dual factor DEMs in B clustered by EPs. (D) Interaction
 751 scores of iDEMs in C. (E) Visual summary of molecular drivers of synergy in B-D plotted including
 752 DEMs, EPs and iDEMs. E_F , feature expression; F_A , factor A; F_B , factor B; F_{AB} , factor AB; FC, fold
 753 change; DEMs, differentially expressed molecules; EPs, expression profiles; iDEMs, interacting DEMs.

Tables and their legends

755

Expression Pattern Response		Fold Change			Expression Profiles
In single factor exposure	In dual factor exposure	F_A	F_B	F_{AB}	
Cooperative	Concordant	↑	↑	↑	I ●
		↓	↓	↓	II ●
	Discordant	↓	↓	↑	III ●
		↑	↑	↓	IV ●
Competitive	Factor A-Dominant	↑	↓	↑	V ●
		↓	↑	↓	VI ●
	Factor B-Dominant	↓	↑	↑	VII ●
		↑	↓	↓	VIII ●

756

757 **Table 1. Expression profiles depict biological interactions during dual factor exposure.**

Expanded View Figure legends

Figure EV1. Overview of model fitting of Omics datasets during analysis with OBIF.

(A) Quality control plots assess data distribution of GSE28994 with violin plots (*top*) and detect potential outliers by hierarchical clustering (*bottom*) in both the pre-processed original dataset (*left*) and the analysis-ready dataset (*right*). (B) Interaction analysis of factorial effects at the whole transcriptome level, demonstrating interaction plots, coefficient significance and goodness of fit per platform. (C) Representative volcano plots of full factorial analysis from analysis ready data for each condition after expression analysis (*top*) and Q-Q plots of moderated t-statistics for each multi-factor effect after contrast analysis (*bottom*). (D) Visual summary of OBIF's outputs including DEMs, EPs and iDEMs (*left*) plotted into 3 rings (*right*): (i) DEMs, where inner links represent shared features between DEMs followed by their $\log_2FC$ values; (ii) EPs, where inner sectors represent individual profiles (I to VIII) followed by their of significant F_A -SME (green), F_B -SME (orange) or $F_A \cdot F_B$ interaction effect (pink); and (iii) iDEMs, represented by their synergistic or antagonistic interaction scores. FC, fold change; DEMs, differentially expressed molecules; EPs, expression profiles; iDEMs, interacting DEMs; SME, simple main effect.

Figure EV2. OBIF analysis of RPPA data from HBEC-3kt treated with single or dual ligands.

(A) Interaction analysis of factorial effects at the whole proteome level, demonstrating interaction plots, coefficient significance and quality of model fitness per platform. (B) Euler diagram of DEMs identified in A. (C) Principal component analysis of dual factor DEMs in B clustered by EPs. (D) OBIF summary of molecular drivers of synergy in B-C. (E) Heatmap of expression values of DEMs in B with expression profiles shown per feature (rows). FC, fold change; DEMs, differentially expressed molecules; EPs, expression profiles.

784 **Figure EV3. STAT family data and gating strategy for imaging flow cytometry.**

785 (A) Transcription factor activity of STAT subunits 15 min after treatment of human lung epithelial cells
786 with Pam2-ODN. n = 3 samples/condition. (B) Gating strategy used during single cell imaging flow
787 cytometry for simultaneous assessment of all transcriptional subunits.

788

789 **Figure EV4. OBIF improves detection of interaction effects across platforms and factor classes.**

790 (A) Comparative performance of data scaling during interaction analysis at the whole “-ome” level
791 showing overall fitness and significance of two-way ANOVA. (B) Significance level of interaction term
792 between factors detected in A. (C) Comparative performance of statistical methods to detect interaction
793 effects at the individual feature level using a beta-uniform mixture model of interaction p-values. (D)
794 Precision and recall fractions at iDEM selection threshold calculated from C. OBIF, Omics-based
795 interaction framework; ROC, receiver operating characteristic; AUC, area under the curve.

A

B

C

D

E

A

Full Factorial Analysis

— Expression Analysis - - - - Contrast Analysis

B

C

D

E

F

G

H

A

Interaction Analysis

$$E_F \sim F_A + F_B + F_A \times F_B$$

Wildtype mouse lungs

Pam2CSK4 + ODN M362

Microarray

RNA-seq

K-ras mutant mouse lungs

Male + Stat3 KO

Reverse Phase
Protein Array

Non-small cell lung cancer (HCC4006)

Volasertib + TGF- β Mass Spectrometry
Metabolomics*Acinetobacter baumannii*

Colistin + Sulbactam

B

DEMs

Factor_A Factor_B Factor_{AB}

C

Expression Profiles

I II III IV V VI VII VIII

D

iDEMs

Antagonistic Synergistic

E

OBIF Summary

A

B

C

D

A

B

C

D

E

A

B

A

- Unscaled original data
- Scaled data with OBIF

B

C

- Mixed-effects model
- Full factorial analysis

D